ZYDPLA1
/ Zydus Lifesciences
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 23, 2013
Zydus announces US FDA approval for initiating phase I clinical trials of ‘ ZYDPLA1’: A novel next generation orally active, small molecule DPP-4 inhibitor to treat type 2 diabetes
(Moneycontrol)
- “...announced the Phase I clinical trial approval from the USFDA for ZYDPLA1 - a Next Generation , long - acting DPP - 4 Inhibitor...with a once - a - week dosing regimen, would provide diabetic patients with a more convenient treatment alternative."
Anticipated new P1 trial • FDA event • Diabetes
1 to 1
Of
1
Go to page
1